SCHEDULE: TransCode Therapeutics: Major Holders Convert Preferred Stock

DEFJ, LLC and CK Life Sciences Int'l. (Holdings) Inc. have converted substantial preferred stock into common shares, increasing their beneficial ownership.

Summary

• DEFJ, LLC and CK Life Sciences Int'l. (Holdings) Inc. (collectively, the Reporting Persons) have amended their Schedule 13D filing regarding TransCode Therapeutics, Inc.
• The amendment details the conversion of Series A and Series B Non-Voting Convertible Preferred Stock into common stock.
• DEFJ converted 1,181.3859 shares of Series A Preferred Stock into 11,813,859 shares of Common Stock and 202.0582 shares of Series B Preferred Stock into 2,020,582 shares of Common Stock on August 3, 2026.
• This conversion, along with a prior conversion on July 23, 2026, results in the Reporting Persons beneficially owning 14,134,481 shares of Common Stock.
• This represents approximately 83.9% of the outstanding shares of Common Stock as of July 23, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, indicating significant control and conversion of preferred stock into common stock by major holders, which could signal confidence or a strategic move.

Positives

• Significant conversion of preferred stock to common stock by major holders, increasing their stake and control.
• Reporting persons now beneficially own 14,134,481 shares, representing 83.9% of the outstanding common stock.
• The company's Board of Directors and a majority of preferred stock holders consented to changes in the Certificate of Designation.
• Waiver of the beneficial ownership limitation by DEFJ, allowing for the conversion.

Negatives

• The filing does not detail the financial performance of TransCode Therapeutics, Inc.
• The significant concentration of ownership by a few entities could limit liquidity or influence for other shareholders.

Risks

• The high percentage of ownership by a single group could lead to decisions not aligned with minority shareholders.
• Changes to the Certificate of Designation, while approved, could have unforeseen implications for future share structures or rights.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future financial performance or strategic direction. The focus is on ownership changes and corporate structure amendments.

Management Comments

• The Second Amended and Restated Certificate of Designation amended Section 6.3.3 of the Amended and Restated Certificate of Designation to remove the requirement of 60 days' notice to change and/or waive the beneficial ownership limitation.
• DEFJ submitted an irrevocable conversion notice to convert Series A and Series B Preferred Stock into Common Stock.

Industry Context

StockSavvy.ai notes that significant shifts in beneficial ownership, particularly through the conversion of preferred securities, can be a precursor to strategic actions or reflect a change in the perceived value of the company's common stock. This is common in biotechnology or development-stage companies where financing structures are complex.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased concentration of ownership may impact voting power and potential for future strategic decisions affecting share value.
• Creditors: No direct impact mentioned, but significant ownership changes could indirectly influence company strategy and financial stability.
• Management: May face increased influence from major shareholders regarding corporate strategy and governance.

Next Steps

• The Reporting Persons will continue to hold a significant stake in TransCode Therapeutics, Inc.
• Further actions by DEFJ and CK Life Sciences Int'l. (Holdings) Inc. regarding their investment will be subject to Schedule 13D reporting requirements.

Key Dates

Recommendation

The filing indicates a significant increase in beneficial ownership by major holders through preferred stock conversion, consolidating control. While this could signal confidence, it doesn't provide new operational or financial data to warrant a buy or sell recommendation. It suggests a stable, albeit concentrated, ownership structure.

Keywords

TransCode Therapeutics, Schedule 13D, Convertible Preferred Stock, Beneficial Ownership, Common Stock, DEFJ LLC, CK Life Sciences